Functional selectivity of GPCR signaling in animals

Current Opinion in Cell Biology

Volumn 27, Issue 1, 2014, Pages 102-108

  Zhou, Lei ^a   Bohn, Laura M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; G PROTEIN COUPLED RECEPTOR; BETA ARRESTIN; RETINA S ANTIGEN;

IN VIVO STUDY; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DEFICIENCY; ENZYME SPECIFICITY; GENETICS; METABOLISM; MOUSE;

ANIMALIA;

ANIMALS; ARRESTINS; MICE; MICE, KNOCKOUT; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84890890929     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.11.010     Document Type: Review

References (56)

1. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
2. Kenakin T. Biased agonism. F1000 Biol Rep 2009, 1:87. 10.3410/B3411-3487.
3. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007, 28:416-422.
4. Mailman R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007, 28:390-396.
5. Bohn L.M. Selectivity for G protein or arrestin-mediated signaling. Functional selectivity of G protein-coupled receptor ligands 2009, 71-85. Humana Press. 1st ed. K.A. Neve (Ed.).
6. Raehal K.M., Schmid C.L., Groer C.E., Bohn L.M. Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 2011, 63:1001-1010.
7. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011, 336:296-302.
8. Kohout T.A., Lin F.S., Perry S.J., Conner D.A., Lefkowitz R.J. Beta-arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci U S A 2001, 98:1601-1610.
9. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005, 258:94-114.
10. Walters R.W., Shukla A.K., Kovacs J.J., Violin J.D., DeWire S.M., Lam C.M., Chen J.R., Muehlbauer M.J., Whalen E.J., Lefkowitz R.J. Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009, 119:1312-1321.
11. Kamanna V.S., Ganji S.H., Kashyap M.L. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009, 63:1369-1377.
12. DeWire S.M., Violin J.D. Biased ligands for better cardiovascular drugs: dissecting G protein-coupled receptor pharmacology. Circ Res 2011, 109:205-216.
13. Lauring B., Taggart A.K., Tata J.R., Dunbar R., Caro L., Cheng K., Chin J., Colletti S.L., Cote J., Khalilieh S., et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med 2012, 4:148ra115.
14. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
15. Bohn L.M., Gainetdinov R.R., Lin F.T., Lefkowitz R.J., Caron M.G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408:720-723.
16. Bohn L.M., Dykstra L.A., Lefkowitz R.J., Caron M.G., Barak L.S. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 2004, 66:106-112.
17. Raehal K.M., Bohn L.M. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 2011, 60:58-65.
18. Bohn L.M., Gainetdinov R.R., Caron M.G. G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. Neuromol Med 2004, 5:41-50.
19. Groer C.E., Schmid C.L., Jaeger A.M., Bohn L.M. Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem 2011, 286:31731-31741.
20. Schulz S., Mayer D., Pfeiffer M., Stumm R., Koch T., Hollt V. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J 2004, 23:3282-3289.
21. Raehal K.M., Walker J.K., Bohn L.M. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 2005, 314:1195-1201.
22. Bohn L.M., Raehal K.M. Opioid receptor signaling: relevance for gastrointestinal therapy. Curr Opin Pharmacol 2006, 6:559-563.
23. Groer C.E., Tidgewell K., Moyer R.A., Harding W.W., Rothman R.B., Prisinzano T.E., Bohn L.M. An opioid agonist that does not induce mu-opioid receptor - arrestin interactions or receptor internalization. Mol Pharmacol 2007, 71:549-557.
24. Lamb K., Tidgewell K., Simpson D.S., Bohn L.M., Prisinzano T.E. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 2012, 121:181-188.
25. DeWire S.M., Yamashita D.S., Rominger D.H., Liu G., Cowan C.L., Graczyk T.M., Chen X.T., Pitis P.M., Gotchev D., Yuan C., et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 2013, 344:708-717.
26. Schmid C.L., Bohn L.M. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 2010, 30:13513-13524.
27. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
28. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011, 63:182-217.
29. Allen J.A., Yost J.M., Setola V., Chen X., Sassano M.F., Chen M., Peterson S., Yadav P.N., Huang X.P., Feng B., et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A 2011, 108:18488-18493.
30. Cupp M.E., Nayak S.K., Adem A.S., Thomsen W.J. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J Pharmacol Exp Ther 2013, 345:404-418.
31. Gesty-Palmer D., Chen M., Reiter E., Ahn S., Nelson C.D., Wang S., Eckhardt A.E., Cowan C.L., Spurney R.F., Luttrell L.M., et al. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 2006, 281:10856-10864.
32. Gesty-Palmer D., Flannery P., Yuan L., Corsino L., Spurney R., Lefkowitz R.J., Luttrell L.M. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 2009, 1:1ra1.
33. Bohinc B.N., Gesty-Palmer D. beta-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption. Endocr Metab Immune Disord Drug Targets 2011, 11:112-119.
34. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 2011, 17:126-139.
35. Tallman K.R., Grandy D.K. A decade of pharma discovery delivers new tools targeting trace amine-associated receptor 1. Neuropsychopharmacology 2012, 37:2553-2554.
36. Sotnikova T.D., Caron M.G., Gainetdinov R.R. Trace amine-associated receptors as emerging therapeutic targets. Mol Pharmacol 2009, 76:229-235.
37. Espinoza S., Salahpour A., Masri B., Sotnikova T.D., Messa M., Barak L.S., Caron M.G., Gainetdinov R.R. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol 2011, 80:416-425.
38. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., Devree B.T., Rosenbaum D.M., Thian F.S., Kobilka T.S., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
39. Steyaert J., Kobilka B.K. Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol 2011, 21:567-572.
40. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
41. Irannejad R., Tomshine J.C., Tomshine J.R., Chevalier M., Mahoney J.P., Steyaert J., Rasmussen S.G., Sunahara R.K., El-Samad H., Huang B., et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature 2013, 495:534-538.
42. Scherrer G., Imamachi N., Cao Y.Q., Contet C., Mennicken F., O'Donnell D., Kieffer B.L., Basbaum A.I. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009, 137:1148-1159.
43. Pradhan A.A., Becker J.A., Scherrer G., Tryoen-Toth P., Filliol D., Matifas A., Massotte D., Gaveriaux-Ruff C., Kieffer B.L. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS ONE 2009, 4:5425e.
44. Gaveriaux-Ruff C., Nozaki C., Nadal X., Hever X.C., Weibel R., Matifas A., Reiss D., Filliol D., Nassar M.A., Wood J.N., et al. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 2011, 152:1238-1248.
45. Nozaki C., Le Bourdonnec B., Reiss D., Windh R.T., Little P.J., Dolle R.E., Kieffer B.L., Gaveriaux-Ruff C. delta-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther 2012, 342:799-807.
46. Butcher A.J., Tobin A.B., Kong K.C. Examining site-specific GPCR phosphorylation. Methods Mol Biol 2011, 746:237-249.
47. Tobin A.B., Butcher A.J., Kong K.C. Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling. Trends Pharmacol Sci 2008, 29:413-420.
48. Doll C., Konietzko J., Poll F., Koch T., Hollt V., Schulz S. Agonist-selective patterns of micro-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 2011, 164:298-307.
49. Just S., Illing S., Trester-Zedlitz M., Lau E.K., Kotowski S.J., Miess E., Mann A., Doll C., Trinidad J.C., Burlingame A.L., et al. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol 2013, 83:633-639.
50. Grecksch G., Just S., Pierstorff C., Imhof A.K., Gluck L., Doll C., Lupp A., Becker A., Koch T., Stumm R., et al. Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A mu-opioid receptor knock-in mice. J Neurosci 2011, 31:13890-13896.
51. Schmid C.L., Streicher J.M., Groer C.E., Munro T.A., Zhou L., Bohn L.M. Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at kappa-opioid receptors in striatal neurons. J Biol Chem 2013, 288:22387-22398.
52. Hoffert J.D., Pisitkun T., Saeed F., Song J.H., Chou C.L., Knepper M.A. Dynamics of the G protein-coupled vasopressin V2 receptor signaling network revealed by quantitative phosphoproteomics. Mol Cell Proteomics 2012, 11. M111 014613.
53. Stockton S.D., Devi L.A. An integrated quantitative proteomics and systems biology approach to explore synaptic protein profile changes during morphine exposure. Neuropsychopharmacology 2013, 38:1-16.
54. Xiao K., McClatchy D.B., Shukla A.K., Zhao Y., Chen M., Shenoy S.K., Yates J.R., Lefkowitz R.J. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A 2007, 104:12011-12016.
55. Gesty-Palmer D., Yuan L., Martin B., Wood W.H., Lee M.H., Janech M.G., Tsoi L.C., Zheng W.J., Luttrell L.M., Maudsley S. Beta-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol 2013, 27:296-314.
56. Bohinc B.N., Gesty-Palmer D. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism. Mini Rev Med Chem 2012, 12:856-865.